Michael Fenn
Venture Partner at Iaso Ventures
Greater Boston
Overview
Work Experience
Head Investor Relations & External Innovation - Senior Director
2021 - Current
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.
Raised $287,000,000.00 from SoftBank Vision Fund, Mirae Asset Capital, Polaris Partners, General Catalyst, Leaps by Bayer, Maverick Ventures, ARCH Venture Partners, NS Investment, Samsara BioCapital and 3E Bioventures.
Venture Partner
2022
Innovation Fellow
2021
Director Healthcare & Life Sciences
2019 - 2021
Scientific Advisor
2020
Venture capital fund helping entrepreneurs launch exponential organizations generally with an impact or sustainability element.
Scientific Advisory Board
2020
CytoVeris develops optical-based probes enabling surgical oncologists to identify and remove tumor tissue during cancer resection surgery.
Raised $8,028,008.00 from MedTech Innovator.
Scientific Advisory Board
2020
Nextnet is a Silicon Valley Venture-backed Generative AI technology startup.
Raised $1,300,000.00 from Propel(X), On Deck and Hike Ventures.
Scientific Advisory Board
2020
Founder & Principal
2010
Scientific Advisory Board
2018 - 2021
Nexien BioPharma develops cannabinoid based medications for specific medical conditions and disorders.
Scientific Advisory Board
2017 - 2020
Jointechlabs develops regenerative medicine therapies such as MiniTC® & Mini-Stem System® - devices to process body fat in non-surgical use.
Raised $2,225,000.00 from Newchip Accelerator, SOSV, EXPERT DOJO, IndieBio, EXPERT DOJO, IndieBio and Stemtech LLC.